Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have received a consensus rating of “Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $31.86.
BCAX has been the subject of several analyst reports. Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 27th. HC Wainwright reduced their price target on Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating for the company in a research report on Friday, May 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Wells Fargo & Company raised Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price objective on the stock in a research note on Friday, May 23rd. Finally, Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a report on Friday, May 23rd.
Read Our Latest Stock Analysis on Bicara Therapeutics
Bicara Therapeutics Stock Down 1.2%
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). As a group, equities research analysts anticipate that Bicara Therapeutics will post -2.59 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Rhumbline Advisers increased its stake in Bicara Therapeutics by 21.1% during the first quarter. Rhumbline Advisers now owns 23,018 shares of the company’s stock valued at $300,000 after acquiring an additional 4,010 shares during the period. Woodline Partners LP boosted its position in shares of Bicara Therapeutics by 26.5% during the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock valued at $4,543,000 after acquiring an additional 72,998 shares in the last quarter. AQR Capital Management LLC acquired a new position in Bicara Therapeutics in the first quarter worth about $248,000. Vestal Point Capital LP boosted its holdings in Bicara Therapeutics by 290.0% during the first quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company’s stock valued at $36,080,000 after purchasing an additional 2,058,975 shares in the last quarter. Finally, Braidwell LP raised its holdings in shares of Bicara Therapeutics by 8.1% in the 1st quarter. Braidwell LP now owns 2,162,803 shares of the company’s stock worth $28,181,000 after buying an additional 162,144 shares in the last quarter.
About Bicara Therapeutics
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Stories
- Five stocks we like better than Bicara Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- GE Aerospace Turns Engines Into Long-Term Profits
- 3 Dividend Kings To Consider
- Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes
- What Are Some of the Best Large-Cap Stocks to Buy?
- Marvell’s New AI Chip Deals Capture Wall Street’s Attention
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.